Update: The FDA Missed Its Self-Imposed Deadline to Ban Formaldehyde in Hair Straighteners

UPDATE (January 5, 2026): The future of the Food and Drug Administration (FDA) 's proposed ban on hair-straightening products ...
Becker's Hospital Review

5 updates on FDA’s expedited drug review activity

The FDA has fast-tracked six therapies since December 2025 through its priority review and National Priority Voucher programs, including the first approval issued under the agency’s new pilot pathway.
Stocktwits on MSN

GH Research stock grabs retail spotlight ahead of FDA update on depression treatment

GH Research is scheduled to update on the FDA status of GH001 and outline its global Phase 3 plans for treatment-resistant ...
Ophthalmology Times

FDA update: Outlook Therapeutics receives CRL for resubmitted ONS-5010 BLA

The FDA issued a CRL for ONS-5010, citing the need for additional confirmatory efficacy evidence despite previous trials ...
Flow Space on MSN

Update: FDA approves oral version of Wegovy, first GLP-1 pill approved specifically for weight management

Just before the end of 2025, an oral version of a GLP-1 drug specifically used for weight management moved much closer to reality. On December 22, the U.S. Food and Drug Administration (FDA) approved ...
Staten Island Advance

FDA updates risk level for major recall of shredded cheese

The U.S. Food and Drug Administration has updated the risk level for a major recall of shredded cheese products. Thousands of pounds of shredded cheese distributed by Great Lakes Cheese Co. Inc. were ...
Monthly Prescribing Reference

FDA Updates Safety Warnings, Restricts DMD Indication for Elevidys

A Boxed Warning was included in the prescribing information highlighting the risk of serious liver injury and acute liver failure. The Food and Drug Administration (FDA) has approved new safety ...

Omeros surges on FDA nod for transplant therapy (update)

Omeros (OMER) stock in focus as the FDA approves its lead asset as Yartemlea for a complication related to stem cell ...
Seeking Alpha

Spectral Medical Inc. (EDT:CA) Discusses Year-End Update: FDA Filing Timeline, Tigris Trial Results, and Commercialization Readiness Transcript

Ali Mahdavi - Spinnaker Capital Markets Inc. Scott McAuley - Paradigm Capital Inc., Research Division Greetings. Welcome to Spectral Medical Year-end 2025 Corporate Update End Year Review Call.
Morningstar

FDA Approves Merck's Keytruda with Padcev to Treat Bladder Cancer — Update

The Food and Drug Administration approved Merck's Keytruda in combination with Padcev to treat certain adults with muscle invasive bladder cancer (MIBC). The FDA said Friday it has approved the drug ...